MX2012005441A - Uso de composiciones que contienen luteina para mejorar ciertos aspectos de la memoria. - Google Patents

Uso de composiciones que contienen luteina para mejorar ciertos aspectos de la memoria.

Info

Publication number
MX2012005441A
MX2012005441A MX2012005441A MX2012005441A MX2012005441A MX 2012005441 A MX2012005441 A MX 2012005441A MX 2012005441 A MX2012005441 A MX 2012005441A MX 2012005441 A MX2012005441 A MX 2012005441A MX 2012005441 A MX2012005441 A MX 2012005441A
Authority
MX
Mexico
Prior art keywords
memory
certain aspects
containing compositions
lutein
improve certain
Prior art date
Application number
MX2012005441A
Other languages
English (en)
Other versions
MX353505B (es
Inventor
Regina Goralczyk
Hasan Mohajeri
Annis Olivia Maynemechan
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of MX2012005441A publication Critical patent/MX2012005441A/es
Publication of MX353505B publication Critical patent/MX353505B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Esta invención se relaciona a un método de incremento de un aspecto de la memoria en un individuo saludable, caracterizado porque el aspecto de memoria se selecciona de un grupo que consiste de: memoria asociativa, memoria espacial y memoria bajo estrés que comprende: administrar una composición que consiste de: a) una cantidad efectiva de ya sea luteína o una combinación de luteína y zeaxantina; y b) un portador apropiado; y observar el incremento de la memoria asociativa, memoria espacial o memoria bajo estrés.
MX2012005441A 2009-11-09 2010-11-05 Uso de composiciones que contienen luteina para mejorar ciertos aspectos de la memoria. MX353505B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27282309P 2009-11-09 2009-11-09
PCT/EP2010/066949 WO2011054944A1 (en) 2009-11-09 2010-11-05 Use of lutein containing compositions to improve certain aspects of memory

Publications (2)

Publication Number Publication Date
MX2012005441A true MX2012005441A (es) 2012-07-03
MX353505B MX353505B (es) 2018-01-17

Family

ID=43304680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005441A MX353505B (es) 2009-11-09 2010-11-05 Uso de composiciones que contienen luteina para mejorar ciertos aspectos de la memoria.

Country Status (8)

Country Link
US (1) US20120232162A1 (es)
EP (1) EP2498765A1 (es)
JP (1) JP6163682B2 (es)
KR (1) KR101766932B1 (es)
CN (2) CN107050000A (es)
BR (1) BR112012010964A2 (es)
MX (1) MX353505B (es)
WO (1) WO2011054944A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201508975SA (en) * 2013-05-24 2015-12-30 Meiji Co Ltd Motility function-improving agent
EP3265069A4 (en) 2015-03-02 2018-11-07 OmniActive Health Technologies Limited Method for stress management and overall health status improvement and compositions used therein
CN110691590A (zh) * 2017-06-01 2020-01-14 参天制药株式会社 用于预防和/或改善脑功能障碍的含有叶黄素类或其盐和菱属植物的加工产物的组合物
NL2019436B1 (en) 2017-08-23 2019-03-07 Newtricious Bv Composition comprising a xantophyll and an omega-3 fatty acid and method of use thereof
JPWO2020066991A1 (ja) 2018-09-28 2021-08-30 株式会社大塚製薬工場 アカルボース又はスタキオースを含む哺乳動物細胞保存用液
CN111838321A (zh) * 2020-08-18 2020-10-30 青岛大学 一种含叶黄素和益生元的老年营养包及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224029A (ja) * 1994-02-09 1995-08-22 Sogo Biyou Ikagaku Kenkyusho:Kk 抗酸化活性をもつカロチノイド含有エキス、その製造法及び抗酸化剤
US6572899B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US20060205826A1 (en) * 2005-03-09 2006-09-14 Romero Francisco J Method of using carotenoids in the prevention of cognitive decline and for other neuroprotection functions
WO2006116755A2 (en) 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
US20100076091A1 (en) * 2007-02-14 2010-03-25 Tohoku University Composition and method for suppressing lipooxidation of erythrocyte

Also Published As

Publication number Publication date
EP2498765A1 (en) 2012-09-19
US20120232162A1 (en) 2012-09-13
CN102612364A (zh) 2012-07-25
KR20120115253A (ko) 2012-10-17
CN107050000A (zh) 2017-08-18
WO2011054944A1 (en) 2011-05-12
JP6163682B2 (ja) 2017-07-19
KR101766932B1 (ko) 2017-08-09
MX353505B (es) 2018-01-17
JP2013510129A (ja) 2013-03-21
BR112012010964A2 (pt) 2018-09-11

Similar Documents

Publication Publication Date Title
CA2863681A1 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
SG169988A1 (en) Rnai inhibition of alpha-enac expression
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
GB0920703D0 (en) Compositions containing satiogens and methods of use
MY148496A (en) Dpp iv inhibitor formulations
MX353505B (es) Uso de composiciones que contienen luteina para mejorar ciertos aspectos de la memoria.
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
UA111065C2 (uk) Композиції норибогаїну
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
MX2013004061A (es) Analogos de ciclosporina.
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2013004062A (es) Analogos de ciclosporina.
PH12017502404A1 (en) Musk compositions and methods of use thereof
MX341623B (es) Composiciones y metodos para mejorar las pestañas.
EP2576536A4 (en) INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE
MX2010001693A (es) Composicion pulverizable que contiene extracto de hojas de parra rojas.
TW201129394A (en) Composition for inhibiting melanogenesis and use thereof
PH12015501251A1 (en) Compositions and methods for treating dental caries
EA201200889A1 (ru) Пептид
WO2009158387A3 (en) Compositions, formulations, and methods for preventing and/or treating physical effects of alcohol consumption
AU2018256632A1 (en) RNAi inhibition of alpha-ENaC expression
UA97521C2 (ru) и-РНК-АГЕНТ, КОТОРЫЙ ОПОСРЕДУЕТ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
UA96034C2 (en) Use of 4,3'-spiro[(2-amino-3-cyano-4,5-dihydropyrano[3,2-c]chromene-5-one-5-methyl-2'-oxyindole] as cerebroprotective agent
PH12014501092B1 (en) 5,5-dimethyl-2-propyl-hexahydro-2,4a-methanonaphthalene-1-one as a fragrance agent

Legal Events

Date Code Title Description
FG Grant or registration